A Decade of Data Protection for Innovative Drugs in Canada: Issues, Limitations, and Time for a Reassessment [0.03%]
加拿大创新药物的数据保护：十年的议题、局限性及重新评估时机
Megan Kendall,Declan Hamill
Megan Kendall
Drug regulators in Canada and in other nations require innovative pharmaceutical companies to submit undisclosed clinical or other data as a condition of approving the marketing of new pharmaceutical products-the origination of which involv...
Innovative Medicines Initiative (IMI) Case Study Analysis Reveals the True Added Value of Early-Phase Public-Private Partnerships (PPPs) [0.03%]
创新药物倡议（IMI）案例研究分析揭示了早期公私合作模式（PPP）的真正附加价值
Hilde Stevens,Geertrui Van Overwalle,Bart Van Looy et al.
Hilde Stevens et al.
Do Biotech Patent Lawsuits Really "Overwhelmingly Lose?": A Response to Our Divided Patent System [0.03%]
生物技术专利诉讼真的是“惨败”吗？对“分裂的专利制度”的回应
Christopher M Holman
Christopher M Holman
Erin E Kepplinger
Erin E Kepplinger
Claim Construction Cannot Save a Modified Gene Invention Claimed with a Scientifically Debatable Biological Mechanism: A Lesson from Bayer CropScience AG v. Dow AgroSciences LLC, 728 F.3d 1324 (Fed. Cir. 2013) [0.03%]
_claim construction不能拯救一个以科学上可质疑的生物机制主张的基因修改发明——拜耳作物科学公司诉陶氏农科公司案（联邦巡回上诉法院，2013年）_的启示
Ping-Hsun Chen
Ping-Hsun Chen
Recent Decisions of the European Court of Justice of the European Union on Supplementary Protection Certificates: A Few Answers-Many Questions [0.03%]
欧洲法院关于补充保护证书的近期判决：几多回应？几多疑问？
Franz-Josef Zimmer,Benjamin Quest,Markus Grammel
Franz-Josef Zimmer
New President, New Human Embryonic Stem Cell Research Policy: Comparative International Perspectives and Embryonic Stem Cell Research Laws in France* [0.03%]
新总统与新人类胚胎干细胞研究政策：来自国际的视角以及法国的胚胎干细胞研究法律
By Katherine Drabiak-Syed
By Katherine Drabiak-Syed
This article provides an overview of French legislative history, Parliamentary debates, and recent amendments in hESC research policy, as well as additional comparisons with laws across the European Union. Unlike policy discussions in the U...